# A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years

Source: https://onco.cc/trials/nct06041061/  
OnCo record `nct06041061` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell） in advanced solid tumours, run by Sinocelltech Ltd., active and no longer recruiting.

## Summary

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years is a phase 3 interventional study registered as NCT06041061 by Sinocelltech Ltd., with 18000 participants enrolled, started 2023-08-13 and due to reach its primary completion in 2024-03. Interventions recorded: Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell） and placebo.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06041061
- Phase: 3
- Setting: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating the Efficacy, Safety, and Immunogenicity of a 14- Valent Recombinant Human Papillomavirus Vaccine (SCT1000) in Healthy Women Aged 18-45 Years
- Sponsor: Sinocelltech Ltd.
- Enrolled: 18000

## Sources

- ClinicalTrials.gov NCT06041061: https://clinicaltrials.gov/study/NCT06041061

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Sinocelltech](https://onco.cc/companies/sinocelltech/)

---
JSON: https://onco.cc/api/v1/entities/nct06041061.json